Adherium (ASX:ADR) Posts Fourth Straight Record Quarter of Hailie Subscription Revenue

Aditi Sarkar

09 November 2026 04:59 PM AEDT

Adherium (ASX:ADR) Posts Fourth Straight Record Quarter of Hailie Subscription Revenue

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Adherium shares were trading at A$0.052 on 9 November 2026, valuing the company at about A$2.85 million.
Recurring remote patient monitoring Revenue reached a record A$479,000, up 39% from the March quarter.
Cumulative activations rose to 3,831 patients, supported by a pipeline of about 68,000 insurance-verified asthma patients.
The company targets about 10,000 remote monitoring device shipments by 31 December 2026, subject to changing assumptions.

Adherium Limited (ASX:ADR) was trading at A$0.052 on 9 November 2026, giving the respiratory technology company a Market Capitalisation of about A$2.85 million. The share price remains sharply lower over twelve months, reflecting the company's tight cash position even as its commercial metrics improve. Its Appendix 4C for the June 2026 quarter showed rapid growth in subscription revenue from the US-focused Hailie remote patient monitoring platform.

Fourth Consecutive Record Quarter

Recurring subscription revenue from remote patient monitoring (RPM) reached A$479,000 in the quarter ended 30 June 2026, up 39% from A$344,000 in the March quarter. The company described it as the fourth consecutive quarter of record RPM revenue. The figure is accrual-based and excludes device sales.

Customer cash receipts rose 79% to A$408,000, from A$228,000 in the prior quarter. A further receipt of A$264,000 from the AstraZeneca Arrival study was due in the September 2026 quarter.

Device and Patient Growth

Adherium shipped 1,684 devices during the quarter, lifting cumulative shipments to 5,302. Activations in the quarter were 1,215, taking cumulative activated patients to 3,831. Management cited a 55.7% compound quarterly growth rate in activations since 30 June 2025.

The company reported a pipeline of about 68,000 insurance-verified, device-compatible asthma patients. Its Hailie Sensor and Smartinhaler technology also featured in data presented at the American Thoracic Society conference in May 2026, including interim results from an independent Intermountain Health study. Clinical data referenced is preliminary, and further evaluation is ongoing.

Funding Remains the Key Question

Net operating cash outflow was A$3.91 million for the quarter and A$14.88 million for the twelve months. Cash at 30 June 2026 was about A$1.38 million, down from A$2.96 million at 31 March 2026. There were no Equity proceeds in the quarter, although year-to-date equity proceeds were A$11.28 million before transaction costs.

Loans from Trudell totalling A$2.69 million were drawn at quarter end at 12% interest. The company's own estimate showed 0.35 quarters of funding at the current rate of outgoings, and it said it is confident it will continue to raise sufficient funds without identifying a specific raise.

Hailie Care and Regulatory Position

The Hailie Care platform connects patients with chronic respiratory conditions to care teams. The company noted that Hailie Care is not approved for commercial Supply in Australia, so current commercial activity centres on the United States, where the Hailie platform holds FDA clearance.

Future Outlook

Adherium's calendar 2026 target of about 10,000 RPM device shipments is based on current assumptions and may change due to risks and uncertainties. Progress toward value-based care contracts in the United States could support recurring revenue, but the near-term outlook depends on securing additional capital. Investors should review the company's September 2026 Quarterly Report for its latest cash position.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.